Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-25-023639
Filing Date
2025-11-14
Accepted
2025-11-14 17:16:14
Documents
77
Period of Report
2025-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q form10-q.htm   iXBRL 10-Q 1908793
2 EX-31.1 ex31-1.htm EX-31.1 12704
3 EX-31.2 ex31-2.htm EX-31.2 12406
4 EX-32.1 ex32-1.htm EX-32.1 7025
5 EX-32.2 ex32-2.htm EX-32.2 7245
  Complete submission text file 0001493152-25-023639.txt   10104703

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE qlgn-20250930.xsd EX-101.SCH 75019
7 XBRL CALCULATION FILE qlgn-20250930_cal.xml EX-101.CAL 63289
8 XBRL DEFINITION FILE qlgn-20250930_def.xml EX-101.DEF 336334
9 XBRL LABEL FILE qlgn-20250930_lab.xml EX-101.LAB 596459
10 XBRL PRESENTATION FILE qlgn-20250930_pre.xml EX-101.PRE 480150
79 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 1920994
Mailing Address 2042 CORTE DEL NOGAL CARLSBAD CALIFORNIA CA 92011
Business Address 2042 CORTE DEL NOGAL CARLSBAD CALIFORNIA CA 92011 (760) 918-9165
Qualigen Therapeutics, Inc. (Filer) CIK: 0001460702 (see all company filings)

EIN.: 263474527 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37428 | Film No.: 251488208
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)